Pallanti S, Quercioli L, Ramacciotti A
Istituto di Neuroscienze, Università di Firenze, Firenze, Italy.
Eat Weight Disord. 1997 Dec;2(4):216-21. doi: 10.1007/BF03339979.
Thirthy-two female patients who had been diagnosed as having anorexia nervosa restricting subtype according to the DSM IV (Diagnostic and Statistical Manual of Mental Disorders-IV), were enrolled in a 6-month open trial with citalopram at a starting dose of 20 mg. At the end of the trial, 46.9% of the patients showed a satisfactory response, 34.4% an unsatisfactory response, improvement criteria being weight improvement, menstruation and score reduction on the Symptoms Checklist 90R. Anorectics also showed significant improvement in several Eating Disorder Inventory-2 (EDI-2) scores at the end of the trial, with greater improvement related to satisfactory response to citalopram. Data suggest that SSRI (Selective Serotonin Reuptake Inhibitor) Citalopram could be effective at least in a subgroup of anorectic patients, both on clinically objective and on subjective aspects of anorexia nervosa.
根据《精神疾病诊断与统计手册第四版》(DSM-IV)被诊断为神经性厌食症限制型的32名女性患者,参加了一项为期6个月的西酞普兰开放试验,起始剂量为20毫克。试验结束时,46.9%的患者显示出满意的反应,34.4%的患者反应不满意,改善标准为体重增加、月经恢复以及症状自评量表90R得分降低。厌食症患者在试验结束时,在几个饮食失调问卷-2(EDI-2)得分上也显示出显著改善,与对西酞普兰的满意反应相关的改善更大。数据表明,选择性5-羟色胺再摄取抑制剂(SSRI)西酞普兰至少在厌食症患者的一个亚组中,在神经性厌食症的临床客观和主观方面可能都是有效的。